PRKN and Parkinson disease: So far, inhibition of DUBs has primarily been investigated as a therapeutic target for on PRKN or PINK1-related Parkinson's disease but may also be beneficial in a carefully stratified population of sporadic Parkinson's disease.61 Deferiprone, an iron chelator that induces mitophagy and has shown promise in many preclinical models of Parkinson's disease, is currently in a large multicentre clinical trial (FAIRPARK-II, NCT02655315).62